48 49 Introduction: Hypertension is a leading cause of mortality worldwide and its prevalence is 50 expected to rise over the next decade. Sex differences exist in the epidemiology and the 51 pathophysiology of hypertension. It is well-established that anti-hypertensive treatment can 52 significantly reduce the risk for stroke and other CVD events. However, it remains unclear 53 whether this effect is dependent on sex. In this protocol we outlined a systematic review and 54 meta-analysis to summarize the current evidence evaluating and comparing the effectiveness of 55 anti-hypertensive therapy in 1) reducing blood pressure and 2) preventing cardiovascular 56 morbidity and mortality outcomes specifically in men versus women. 57 58 Methods and analysis: The following electronic databases will be searched: MEDLINE, 59 Embase, The Cochrane Library, PubMed, CINAHL Plus, Web of Science, grey literature 60 (Google Scholar), and several trial registries. Search strategies will be designed to identify 61 human (18+) randomized (and non-randomized) controlled trials, prospective and retrospective 62 cohort studies, and case-control studies concerning 'sex-specific differences associated with the 63 efficacy of anti-hypertensive treatment'. Two investigators will independently review each 64 article included in the final analysis. Primary outcomes investigated are cardiovascular morbidity 65 and mortality and systolic and diastolic blood pressure. Pooled analyses will be conducted using 66 fixed-effects (Mantel-Haenszel) or random-effects (DerSimonian-Laird) models. Publication 67 bias will be assessed by visual inspection of funnel plots and by Begg's and Egger's statistical 68 tests. Between-studies heterogeneity will be measured using the I 2 test. Sources of heterogeneity 69 will be explored by sensitivity, subgroup, and meta-regression analyses. 70 71 Dissemination: This is the first meta-analysis that will directly compare the efficacy of an anti-72 hypertensive treatment regimen between men and women. Findings will be shared through 73 scientific conferences and societies, social media, and consumer advocacy groups. Results will 74 be used to inform the current guidelines for management of hypertension in men and women by 75 demonstrating the importance of implementing sex-specific recommendations. 76 77 No studies will be excluded based on the risk of bias assessment
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Other than as permitted in any relevant BMJ Author' 137 early clinical trials that examined the efficacy of anti-hypertensive medication in blood pressure 138 control and cardiovascular outcomes, collected data in either men alone or combined results for 139 men and women 12 . Since women were heavily under-represented in these trials, any sex-specific 140 analyses that were performed were severely underpowered. As a result, a systematic review that 141 summarized the results from these early trials concluded that the evidence on the efficacy of anti-142 hypertensive treatment specifically in women is weak 13 . Therefore, gaining better understanding 143 of how women respond to anti-hypertensive medication is a clinical priority. 144 Recognizing the importance of implementing sex-specific evidence into clinical practice 145 guidelines, in this protocol we outlined a systematic review and meta-analysis to summarize the 146 current evidence evaluating the effectiveness of anti-hypertensive therapy in 1) reducing blood 147 pressure and 2) preventing cardiovascular morbidity and mortality outcomes for each sex 148 separately. Moreover, we aim to determine whether the treatment effect differs significantly 149 between women and men. 150 151 Methods and design 152 153 Registration: 154 This protocol was written in accordance with the "Preferred Reporting Items for Systematic 155 Review and Meta-Analysis Protocols (PRISMA-P)" guidelines 14 (see check-list in Appendix 1). 156 Our systematic review and meta-analysis protocol will be registered with the International 157 Prospective Register of Systematic Reviews (PROSPERO) after feed-back and peer review. 158 159 Eligibility criteria: 160 Studies will be selected according to the criteria outlined below. 161 162 Study designs 163 We will include randomized controlled trials (RCTs), controlled (non-randomized) clinical trials, 164 prospective and retrospective comparative cohort studies, and case-control or nested case-control 165 studies performed in humans. Cross-sectional studies, case series, case reports, reviews, 166 commentaries, letters, editorials, conference abstracts, and unpublished data will be excluded. 167 All animal and in vitro studies will not be considered. 168 169 Participants 170 We will include studies involving adult men and women (18 years or older) regardless of race or 171 ethnicity, with clinical indication for anti-hypertensive therapy. Other comorbid conditions, in 172 addition to hypertension (as diagnosed using established diagnostic criteria) 15 , will be allowed. 173 However, studies restricted to populations with unrelated conditions/diseases (e.g., cancer) will 174 not be considered. Studies that do not report and authors fail to provide data separately for men 175 and women will be excluded. 176 177 Interventions 178 The intervention will consist of anti-hypertensive medications, which are used for the 179 pharmacologic management of hypertension, as well as the prevention of its complications, such 180 as stroke and myocardial infarction. Several classes of anti-hypertensive regimens exist 181 including, diuretics, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, 182 calcium channel blockers, β-blockers, as first line medications, as well as α-blockers, α-2 To ensure literature saturation, reference lists of eligible studies or of 218 relevant meta-analyses and reviews identified through the search will be hand-searched. 219 220 Search strategy: 221 Literature search strategies will be developed using medical subject headings and text words 222 related to 'sex differences', 'anti-hypertensive medication', and 'blood pressure'. A search 223 strategy will be developed for MEDLINE, and the search terms will be adapted for use with the 224 other bibliographic databases. No date or language limits will be applied on the search. The 225 literature search will be limited to human subjects and adults ≥18 years of age. Conference 226 abstracts, commentaries, and letters will be excluded from the search. Search strategies will be 227 peer-reviewed by two librarians. A draft MEDLINE search strategy is included in Appendix 2. 228 229 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   6 230 Study records: 231 Data management 232 Literature search results will be uploaded to Rayyan, an Internet-based software program that 233 facilitates collaboration among reviewers during the screening process. Prior to uploading to the 234 software, duplicates will be removed. 235 236 Selection process 237 Firstly, two authors, KG and CL, will independently screen the titles and abstracts of studies 238 yielded by the search in order to identify potentially eligible records. They will be unaware of the 239 study's authors' names and journal title to avoid the introduction of a bias in the selection 240 process. Full text reports for all studies that appear to meet the inclusion criteria or where there is 241 any uncertainty will then be screened independently by the same authors (KG and CL) to select 242 studies for final inclusion. Disagreements at all stages of the selection process will be resolved 243 through consensus with the corresponding author (SSD). We will contact study authors via email 244 for additional information where necessary to resolve questions concerning the eligibility of the 245 proposed study. If authors do not respond within four weeks of initial contact, a follow-up email 246 will be sent. If authors do not respond after four weeks of the second contact, the study will not 247 be considered in the analysis. 248 249 Data collection process 250 Data extraction will be performed independently by KG and CL. Data will be preferentially 251 extracted from result tables in the selected articles. If the data are not listed in the tables, the text 252 in the results section will be carefully read for any important information. If the data are only 253 available from graphs, the data will be extracted manually using the Image J® software version 254 1.47t (ImageJ, US National Institutes of Health, Bethesda, MD, http://imagej.nih.gov/ij/, 1997-255 2015). Extracted data will include study and population characteristics, details on blood pressure, 256 intervention details, and patient outcomes of interest. Authors will be contacted in case further 257 information and clarifications are needed using the same strategy as mentioned previously. 258 259 Data items 260 Data items that will be extracted from each included article are presented in Table 1 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 278 Disagreements will be resolved first by discussion and then by consulting a third author (SSD) 279 for arbitration. For cohort and case-control studies risk of bias assessment will be performed 280 using the 9-item Newcastle-Ottawa Quality Assessment Scale. Three parameters will be 281 evaluated: (1) population selection, (2) comparability of results, and (3) ascertainment of 282 exposure or outcome. Similarly, two independent reviewers, KG and CL, will perform each 283 quality assessment, consulting a third reviewer (SSD) when necessary. Studies will be 284 considered of high quality if the total score is ≥7/9. No studies will be excluded based on the risk 285 of bias assessment. 286 287 Data analysis: 288 289 Synthesis 290 Meta-analyses will be conducted separately for men and women to evaluate the effect of anti-291 hypertensive therapy on 1) blood pressure and 2) cardiovascular morbidity and mortality 292 outcomes. Pooled analyses will be conducted using fixed-effects (Mantel-Haenszel) or random-293 effects (DerSimonian-Laird) models and considered significant at P< 0.05. Data concerning 294 systolic and diastolic blood pressure will be expressed as mean differences (with 95% CIs). Data 295 concerning each cardiovascular morbidity and mortality outcome will be expressed as summary 296 RR with 95% CIs. Numbers needed to treat (NNT) estimates, which is the number of patients 297 who must be treated to prevent one adverse outcome, will be calculated. Between-studies 298 heterogeneity will be measured using the I 2 test. The Mantel-Haenszel method will be used for 299 the fixed effect model if tests of heterogeneity are not significant. In case of statistically 300 significant between-studies heterogeneity, the DerSimonian-Laird random-effects model will be 301 applied. 302 303 Sources of heterogeneity will be explored by sensitivity and subgroup analyses, stratifying 304 studies by various factors, including study design, risk of bias, follow-up duration, age (e.g., 305 younger vs older women, younger vs older men, younger women vs younger men, older women 306 vs older men), ethnicity/race, type of hypertension, class of anti-hypertensive therapy, and 307 treatment dosage. Meta-regression analyses will also be performed to assess the effect of 315 Publication bias will be assessed by visual inspection of funnel plots and by Begg's and Egger's 316 statistical tests, if at least 9 studies are available. P< 0.05 will be considered evidence of small 317 study effects. In order to determine whether outcome reporting bias is present, we will evaluate 318 whether the protocol of the RCT was published before recruitment of patients of the study was 319 started. Moreover, we will compare outcomes reported in the protocol and the published report. 320 321 Confidence in cumulative estimate 322 The quality of evidence for all outcomes will be judged using the Grading of Recommendations 323 Assessment, Development and Evaluation (GRADE) Working Group criteria 17 . 324 325 Discussion 326 Hypertension is a major risk factor for CVD, placing it as the most common cause of death 327 world-wide 1,2 . Overwhelming evidence indicates that sex differences exist in the epidemiology 328 and the pathophysiology of hypertension 18 . Specifically, premenopausal women have lower 329 incidence and severity of hypertension, and thus a lower incidence of CVD, than age-matched 330 men 8,9 . However, this cardio-protection is compromised post-menopause, where the risk of 331 hypertension increases sharply in women 8,9 .
332
We expect that this sexual dimorphism may also extend to the treatment efficacy of anti-333 hypertensive medication. It is well-established that anti-hypertensive treatment can significantly 334 reduce the risk for stroke and other CVD events 5 . However, it remains unclear whether this 335 effect is dependent on sex. Moreover, it is not established whether different classes of anti-336 hypertensive drugs routinely used in clinical practice work similarly in men and women. 337 Currently, hypertension guidelines do not report sex-specific recommendations. Evaluation of 338 these differences is required to ensure the best possible care for both men and women living with 339 hypertension. Thus, herein, we provide a protocol of a systematic review and meta-analysis that 340 summarizes the current evidence evaluating sex differences in the efficacy of anti-hypertensive 341 treatment in reducing CVD outcomes and blood pressure. To our knowledge, this is the first 342 meta-analysis that will directly and comprehensively compare the efficacy of anti-hypertensive 343 treatment regimens between men and women. 344 We will share the findings of these meta-analyses through scientific conferences and 345 societies, social media, and consumer advocacy groups. Importantly, the results will be used to 346 inform the current guidelines for management of hypertension in men and women by 347 demonstrating the importance of implementing sex-specific recommendations. It may determine 348 which classes of anti-hypertensive medications may be more effective in men and in women. 349 Treatment strategies for hypertension and CVD that are tailored according to sex could lead to 350 improved outcomes for the affected individuals. 351 352 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
PRISMA-P 2015 Checklist
This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 
in Moher D et al:
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews 2015 4:1
An Editorial from the Editors-in-Chief of Systematic Reviews details why this checklist was adapted -Moher D, Stewart L & Shekelle P: Implementing PRISMA-P: recommendations for prospective authors. Systematic Reviews 2016 5:15 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)
144-149

METHODS
Eligibility criteria 8
Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review 159-208
Information sources 9 Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage
210-218
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated 220-227
STUDY RECORDS
Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 231-234
Selection process 11b State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)
236-247
Data collection process 11c Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators 249-257
Data items 12
List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications
259-261
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale
262-272
Risk of bias in individual studies 14
Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 336361 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 (therap* or treat* or effective*))).tw,kf.
52111
14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or antagonist*)).tw,kf. 20534 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil or deutolperisone or devapamil or dexniguldipine or dexverapamil or diclofurime or diltiazem or diperdipine or diproteverine or dopropidil or dotarizine or efonidipine or elgodipine or elnadipine or emopamil or enecadin or eperisone or etripamil or falipamil or fantofarone or fasudil or felodipine or fendiline or flordipine or flosatidil or fluspirilene or fostedil or furnidipine or gabapentin or gallopamil or iganidipine or isoperisone or isradipine or lacidipine or lemildipine or lercanidipine or lifarizine or lomerizine or manidipine or mepamil or mepirodipine or mesudipine or meta nisoldipine or mibefradil or mirogabalin or modipafant or monatepil or n methylbepridil or n nordiltiazem or naltiazem or nexopamil or nicardipine or nifedipine or niguldipine or niludipine or nilvadipine or nimodipine or nisoldipine or nitrendipine or norgallopamil or norverapamil or olradipine or omega agatoxin or omega conotoxin or oxodipine or palonidipine or perhexiline or pimozide or pinokalant or pontuc or pranidipine or pregabalin or riodipine or ronipamil or sagandipine or semotiadil or silperisone or siratiazem or tamolarizine or teludipine or temiverine or terodiline or tolperisone or trelnarizine or verapamil or watanidipine or xestospongin C or zonisamide).nm,tw,kf. 24 (("Angiotensin-Converting Enzyme" or ACE) adj5 (inhibit* or antagoni*)).tw,kf. 37120 25 ("kininase ii" adj2 (antagoni* or inhibit*)).tw,kf,nm. 150 26 (alacepril or altiopril or ancovenin or benazepril or benazeprilat or captopril or ceranapril or cilazapril or cilazaprilat or deacetylalacepril or delapril or enalapril or enalaprilat or epicaptopril or fasidotril or fasidotrilat or foroxymithine or fosinopril or fosinoprilat or gemopatrilat or idrapril or ilepatril or imidapril or imidaprilat or indolapril or libenzapril or lisinopril or moexipril or moexiprilat or omapatrilat or pentopril or pentoprilat or perindopril or perindoprilat or pivopril or quinapril or quinaprilat or ramipril or ramiprilat or rentiapril or s nitrosocaptopril or sampatrilat or spirapril or spiraprilat or temocapril or temocaprilat or teprotide or trandolapril or trandolaprilat or utibapril or utibaprilat or vasopeptidase inhibitor or zabicipril or zabiciprilat or zofenopril or zofenoprilat).nm,tw,kf. 35 (adaprolol or afurolol or alprenolol or alprenolol derivative or befunolol or beta 1 adrenergic receptor blocking agent or beta 2 adrenergic receptor blocking agent or beta 3 adrenergic receptor blocking agent or bfe 55 or bopindolol or bornaprolol or bromoacetylalprenololmenthane or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or bupranolol or butofilolol or carazolol or carpindolol or carteolol or carvedilol or cloranolol or deacetylmetipranolol or dexpropranolol or diacetolol or dichlorisoprenaline or dihydroalprenolol or dilevalol or diprafenone or ersentilide or exaprolol or falintolol or falintolol oxalate or flestolol or hydroxybenzylpindolol or indenolol or iodopindolol or iprocrolol or isamoltane or isoxaprolol or labetalol or levobunolol or levomoprolol or mepindolol or mercuderamide or metipranolol or moprolol or nadolol or nifenalol or oberadilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol* or primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or soquinolol or soquinolol mucate or sotalol or spirendolol or tazolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or trasitensin or trepress or tribendilol or 72506 The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence -details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.
Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence. Abstract 48 49 Introduction: Hypertension is a leading cause of mortality worldwide and its prevalence is 50 expected to rise over the next decade. Sex differences exist in the epidemiology and 51 pathophysiology of hypertension. It is well-established that anti-hypertensive treatment can 52 significantly reduce the risk for stroke and other CVD events. However, it remains unclear 53 whether this effect is dependent on sex. In this protocol we outlined a systematic review and 54 meta-analysis to evaluate the effects of anti-hypertensive therapy in 1) reducing blood pressure 55 and 2) preventing cardiovascular morbidity and mortality outcomes for each sex separately. 56 57 Methods and analysis: The following electronic databases will be searched: MEDLINE, 58 Embase, The Cochrane Library, PubMed, CINAHL Plus, Web of Science, grey literature 59 (Google Scholar), and several trial registries. Search strategies will be designed to identify 60 human adult (≥18) randomized (and non-randomized) controlled trials, prospective and 61 retrospective cohort studies, and case-control studies concerning 'sex-specific differences 62 associated with the efficacy of anti-hypertensive treatment'. A preliminary search strategy was 63 developed for MEDLINE (1946 ( -September 16, 2019 . Two investigators will independently 64 review each article included in the final analysis. Primary outcomes investigated are 65 cardiovascular morbidity and mortality and systolic and diastolic blood pressure. Pooled analyses 66 will be conducted using the random-effects model. Publication bias will be assessed by visual 67 inspection of funnel plots and by Begg's and Egger's statistical tests. Between-studies 68 heterogeneity will be measured using the I 2 test (P<0.10). Sources of heterogeneity will be 69 explored by sensitivity, subgroup, and meta-regression analyses. 70 71 Ethics and dissemination: This is the first meta-analysis that will comprehensively compare the 72 efficacy of anti-hypertensive treatment regimens between men and women. Findings will be 73 shared through scientific conferences and societies, social media, and consumer advocacy 74 groups. Results will be used to inform the current guidelines for management of hypertension in 75 men and women by demonstrating the importance of implementing sex-specific 76 recommendations.  The first meta-analysis that will comprehensively compare the efficacy of anti-97 hypertensive treatment regimens between men and women 98  There will be no restrictions on the class or dosage of anti-hypertensive medications used 99  No studies will be excluded based on the risk of bias assessment and studies will be 100 analyzed separately based on study design 101  Sources of heterogeneity will be explored by sensitivity and subgroup analyses 102  An individual patient data meta-analysis will not be undertaken and is a limitation of our 103 study 104 105 Abbreviations 106 CVD -cardiovascular disease 107 RR -risk ratio 108 CI -confidence interval 109 RCT -randomized controlled trial 110 111 Introduction 112 Hypertension is a leading cause of mortality worldwide and its prevalence is expected to rise 113 over the next decade in both men and women 1, 2 . While it is estimated that 1.13 billion people 114 worldwide have hypertension, fewer than 1 in 5 people with hypertension are under control 1 . A 115 strong relationship exists between hypertension and cardiovascular disease (CVD), whereby an 116 increase in blood pressure is associated with an increase in the risk of myocardial infarction, 117 stroke, and CVD-related mortality 3,4 . Specifically, a meta-analysis of individual data from 61 118 prospective studies reported that at the ages of 40-69 years, a 20 mmHg increase in systolic 119 blood pressure (or equivalently 10 mmHg increase in diastolic blood pressure) was associated 120 with a 2-fold increase in stroke and ischemic heart disease death rates 3 . Therefore, improving 121 hypertension control rates can considerably reduce the burden of CVD. A meta-analysis 122 combining data from 123 large-scale blood pressure lowering trials demonstrated that anti-123 hypertensive therapy is highly effective in preventing the occurrence of CVD morbidity and 124 mortality; treatment of hypertension was associated with a reduction in the risk of stroke (risk 125 ratio [RR]: 0.73; 95% confidence interval [CI]: 0.68-0.77), coronary heart disease (RR: 0.83; 126 95% CI: 0.78-0.88), heart failure (RR: 0.72; 95% CI: 0.67-0.78), and all-cause mortality (RR: 127 0.87; 95% CI: 0.84-0.91) compared with no drug treatment 5 . 128
Studies indicate that sex differences exist in the relative contribution of cardiovascular 129 risk factors in women and men 6 . Furthermore, the prevalence of hypertension differs between 130 men and women across the life-span 7 . It is well-established that men are more likely to develop 131 hypertension at a younger age compared with premenopausal women 8 . However, after 132 menopause women display a more rapid increase in the prevalence of hypertension relative to 133 men, such that after 60-65 years of age hypertension rates in women exceed those observed in 134 men 8, 9 . As a result, these older women have greater CVD burden than men of similar age 8 . 135 Despite these sex disparities, hypertension is often poorly controlled in older women 10 . 136
Although the bioavailability of cardiovascular drugs may differ by sex 11 , there exists no 137 sex-specific guidelines for hypertension management, as it remains unclear whether the effect of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   4 138 anti-hypertensive treatment in reducing cardiovascular risk is dependent on sex 8 . Many of the 139 early clinical trials that examined the efficacy of anti-hypertensive medication in blood pressure 140 control and cardiovascular outcomes, collected data in either men alone or combined results for 141 men and women 12 . Since women were heavily under-represented in these trials, any sex-specific 142 analyses that were performed were severely underpowered. As a result, a systematic review that 143 summarized the results from these early trials concluded that the evidence on the efficacy of anti-144 hypertensive treatment specifically in women is weak 13 . Therefore, gaining better understanding 145 of how women respond to anti-hypertensive medication is a clinical priority. 146
Recognizing the importance of implementing sex-specific evidence into clinical practice 147 guidelines, in this protocol we outlined a systematic review and meta-analysis to summarize the 148 current evidence evaluating the effects of anti-hypertensive therapy in 1) reducing blood pressure 149 and 2) preventing cardiovascular morbidity and mortality outcomes for each sex separately. 150 Moreover, we aim to determine whether the treatment effect differs significantly between 151 women and men. 152 153 Methods and design 154 155 Registration: 156 This protocol was written in accordance with the "Preferred Reporting Items for Systematic 157 Review and Meta-Analysis Protocols (PRISMA-P)" guidelines 14 (see check-list in Appendix 1). 158 Our systematic review and meta-analysis protocol will be registered with the International 159 Prospective Register of Systematic Reviews (PROSPERO) after feed-back and peer review. 160 161 Eligibility criteria: 162 Studies will be selected according to the criteria outlined below. 163 164 Study designs 165 We will include randomized controlled trials (RCTs), controlled (non-randomized) clinical trials, 166 prospective and retrospective comparative cohort studies, and case-control or nested case-control 167 studies performed in humans. Cross-sectional studies, case series, case reports, reviews, 168 commentaries, letters, editorials, conference abstracts, and unpublished data will be excluded. 169 All animal and in vitro studies will not be considered. 170 171 Participants 172 We will include studies involving adult men and women (18 years or older) regardless of race or 173 ethnicity, with clinical indication for anti-hypertensive therapy 15 . The studies included will be 174 restricted to a hypertensive cohort who received anti-hypertensive treatment strictly for 175 hypertension and not for other cardiovascular conditions (other than hypertension) or non-176 cardiovascular indications (e.g. migraine). If the hypertensive cohorts present with other comorbid 177 conditions, this will be allowed in order to represent clinical reality. However, studies restricted to 178 a specific cohort who is studied after suffering from an acute event (e.g. post-MI, post-stroke, 179 congestive heart failure) or who is on dialysis, will not be considered. Studies that only report sex 180 aggregated data will be excluded. 181 182 183 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 6 231 other bibliographic databases. No date or language limits will be applied on the search. The 232 literature search will be limited to human subjects and adults ≥18 years of age. Conference 233 abstracts, commentaries, and letters will be excluded from the search. Search strategies will be 234 peer-reviewed by two librarians. A draft MEDLINE search strategy is included in Appendix 2. 235 236 Study records: 237 Data management 238 Literature search results will be uploaded to Rayyan, an Internet-based software program that 239 facilitates collaboration among reviewers during the screening process. Prior to uploading to the 240 software, duplicates will be removed. 241 242 Selection process 243 Firstly, two authors, KG and CL, will independently screen the titles and abstracts of studies 244 yielded by the search in order to identify potentially eligible records. They will be unaware of the 245 study's authors' names and journal title to avoid the introduction of a bias in the selection 246 process. Full text reports for all studies that appear to meet the inclusion criteria or where there is 247 any uncertainty will then be screened independently by the same authors (KG and CL) to select 248 studies for final inclusion. Disagreements at all stages of the selection process will be resolved 249 through consensus with the corresponding author (SSD). We will contact study authors via email 250 for additional information where necessary to resolve questions concerning the eligibility of the 251 proposed study. If authors do not respond within four weeks of initial contact, a follow-up email 252 will be sent. If authors do not respond after four weeks of the second contact, the study will not 253 be considered in the analysis. 254 255 Data collection process 256 Data extraction will be performed independently by KG and CL. Data will be preferentially 257 extracted from result tables in the selected articles. If the data are not listed in the tables, the text 258 in the results section will be carefully read for any important information. If the data are only 259 available from graphs, the data will be extracted manually using the Image J® software version 260 1.47t (ImageJ, US National Institutes of Health, Bethesda, MD, http://imagej.nih.gov/ij/, 1997-261 2015). Extracted data will include study and population characteristics, details on blood pressure, 262 intervention details, and patient outcomes of interest. Authors will be contacted in case further 263 information and clarifications are needed using the same strategy as mentioned previously. 264 265 Data items 266 Data items that will be extracted from each included article are presented in Table 1 Outcomes and prioritization 270 To be included, study outcomes have to be available according to sex. For primary outcomes, 271 data involving the change in systolic and diastolic blood pressure (in mmHg) between baseline 272 and follow-up will be extracted, as well as effect estimates for cardiovascular (and 273 cerebrovascular) morbidity and mortality, including fatal and/or non-fatal myocardial infarction, 274 fatal and/or non-fatal stroke, fatal and/or non-fatal heart failure (including hospitalizations), 275 major adverse cardiac events and cardiovascular death. Effect estimates for all-cause mortality 276 will be extracted as a secondary outcome, along with drug compliance (in %), and safety 277 outcomes, i.e., the incidence of adverse events (including but not limited to, allergic reaction/ 278 angioedema/ skin rash, electrolyte disturbances, cough, peripheral edema, diarrhea or 279 constipation, nausea or vomiting, skin rash, agitation or anxiety, insomnia, palpitations), and 280 permanent treatment discontinuations because of adverse events (in %). 281 282 Risk of bias in individual studies 283 Risk of bias assessment for randomized controlled trials will be performed using the modified 284 Cochrane Risk of Bias tool. Judgements, expressed as high, low, or unclear risk, will be made 285 independently by two authors, KG and CL, based on the criteria for judging the risk of bias. 286 Disagreements will be resolved first by discussion and then by consulting a third author (SSD) 287 for arbitration. For cohort and case-control studies, risk of bias assessment will be performed 288 using the 9-item Newcastle-Ottawa Quality Assessment Scale. Three parameters will be 289 evaluated: (1) population selection, (2) comparability of results, and (3) ascertainment of 290 exposure or outcome. Similarly, two independent reviewers, KG and CL, will perform each 291 quality assessment, consulting a third reviewer (SSD) when necessary. Studies will be 292 considered of high quality if the total score is ≥7/9. No studies will be excluded based on the risk 293 of bias assessment. 294 295 Data analysis: 296 297 Synthesis 298 Meta-analyses will be conducted separately for men and women to evaluate the effect of anti-299 hypertensive therapy on 1) blood pressure and 2) cardiovascular morbidity and mortality 300 outcomes. Data concerning systolic and diastolic blood pressure will be expressed as mean 301 differences (with 95% CIs). Data concerning each cardiovascular morbidity and mortality 302 outcome will be expressed as summary RR with 95% CIs. Numbers needed to treat (NNT) 303 estimates, which is the number of patients who must be treated to prevent one adverse outcome, 304 will be calculated. Between-studies heterogeneity will be measured using the I 2 test; significance 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 8,9 . We expect that this sexual dimorphism may also 348 extend to the treatment efficacy of anti-hypertensive medication. It is well-established that anti-349 hypertensive treatment can significantly reduce the risk for stroke and other CVD events 5 . 350 However, it remains unclear whether this effect is dependent on sex. Moreover, it is not 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 9 351 established whether different classes of anti-hypertensive drugs routinely used in clinical practice 352 work similarly in men and women. Currently, hypertension guidelines do not report sex-specific 353 recommendations. Evaluation of these differences is required to ensure the best possible care for 354 both men and women living with hypertension. Thus, herein, we provide a protocol of a 355 systematic review and meta-analysis that summarizes the current evidence evaluating sex 356 differences in the efficacy of anti-hypertensive treatment in reducing CVD outcomes and blood 357 pressure. To our knowledge, this is the first meta-analysis that will comprehensively compare the 358 efficacy of anti-hypertensive treatment regimens between men and women. In addition to 359 analyzing more recent trial data on this topic, than a previously performed meta-analysis of 360 randomized trials (prior to 2006) 21 , we will also include non-randomized and epidemiological 361 evidence, and we will perform several sub-analyses, as appropriate. 362 363 Ethics and dissemination 364 We will share the findings of these meta-analyses through scientific conferences and societies, 365 social media, and consumer advocacy groups. Importantly, the results will be used to inform the 366 current guidelines for management of hypertension in men and women by demonstrating the 367 importance of implementing sex-specific recommendations. It may determine which classes of 368 anti-hypertensive medications may be more effective in men and in women. Treatment strategies 369 for hypertension and CVD that are tailored according to sex could lead to improved outcomes for 370 the affected individuals. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
PRISMA-P 2015 Checklist
This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)
146-151
METHODS
Eligibility criteria 8
Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review
161-215
217-225
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
227-234
STUDY RECORDS
Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 237-240
242-253
Data collection process 11c Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators
255-263
Data items 12
265-268
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale 269-280
Risk of bias in individual studies 14
Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis
282-293
DATA
Synthesis
15a Describe criteria under which study data will be quantitatively synthesized 298-300 15b
If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I 2 , Kendall's tau) Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, metaregression)
300-308
310-321
15d If quantitative synthesis is not appropriate, describe the type of summary planned N/A
Meta-bias(es) 16
Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)
326-331
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